论文部分内容阅读
肿瘤浸润淋巴细胞(TIL)是继LAK细胞之后发现的又一类抗肿瘤免疫活性细胞,它具有更强而特异的抗瘤活性。当前,建立体外获得大量可供临床应用的具有高度而特异抗瘤活性的免疫效应细胞的方法和途径已成为人们致力研究的课题。本文着重介绍了TIL 分离制备和体外培养扩增等方法学研究进展。近年来,已基本建立起TIL 分离制备技术,在IL-2存在下TIL 能够有效增殖达1000倍以上;TIL 经冻存复苏后仍保持较好的增殖和抗瘤活性,这为临床长期应用TIL 提供了可能性。TIL 的研究为临床晚期肿瘤的治疗开辟了新途径。
Tumor infiltrating lymphocytes (TIL) is another type of anti-tumor immune activity cell that is found after LAK cells, and it has stronger and specific anti-tumor activity. At present, the establishment of methods and approaches to obtain a large number of immune effector cells with high and specific anti-tumor activity available for clinical use in vitro has become a research topic. This article focuses on the methodological development of TIL separation preparation and in vitro culture amplification. In recent years, TIL separation and preparation techniques have been basically established. In the presence of IL-2, TIL can effectively proliferate more than 1000-fold; TIL still maintains good proliferation and antitumor activity after cryopreservation, which is a long-term clinical application of TIL. Offers possibilities. The TIL study has opened up new avenues for the treatment of clinically advanced tumors.